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ABSTRACT
Even if the true incidence of hypoglycemia in 
type 2 diabetes mellitus (T2DM) remains difficult 
to estimate, with highly variable rates reported 
in the literature, it is likely more common than 
previously thought. While most hypoglycemic 
episodes in T2DM are considered “mild,” they 
still have a substantial clinical impact. Severe 
hypoglycemia also exists in T2DM, with recent 
landmark studies prompting much debate about 
the potential role of severe hypoglycemia in 
cardiovascular morbidity and mortality, even 
though there is currently no definitive evidence 
for causality. The challenge in the treatment 
of T2DM remains the achievement of optimal 
glycemic control to lower the risk for long-term 
complications while avoiding hypoglycemia. 
Successful treatment strategies should therefore 
include careful selection of therapies to prevent 
hypoglycemia, starting early in the disease 
management process, in order to best preserve 
counterregulation. The dipeptidyl peptidase-4 
inhibitor, vildagliptin, is a good treatment 
option to minimize the risk of hypoglycemia 
over time, while maintaining good glucose 
control. Extensive clinical experience is available 
for vildagliptin, with data published for all stages 
of the condition and with the low hypoglycemic 
potential stemming from a solid mechanistic 
basis.
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DEFINITION, FREQUENCY, AND 
SEVERITY OF HYPOGLYCEMIA IN 
TYPE 2 DIABETES MELLITUS: THE 
SCOPE OF THE PROBLEM
Hypoglycemia is a common problem in 
patients with type 2 diabetes mellitus (T2DM), 
occurring most frequently with medications 
that raise insulin levels independently of blood 
glucose, such as oral insulin secretagogues 
(sulfonylureas and glinides) and exogenous 
insulin. Unfortunately, there is no consensus 
definition of hypoglycemia in diabetes,152 Diabetes Ther (2011)  2(2):51-66.
and no standard definition of hypoglycemia 
has been used in clinical trials, making it 
difficult to assess its incidence, with substantial 
variation in reported rates.2 The American 
Diabetes Association (ADA) Workgroup on 
Hypoglycemia3 defined hypoglycemia as “any 
abnormally low plasma glucose concentration 
that exposes the subject to potential harm” 
with a proposed threshold of plasma glucose 
<70 mg/dL (<3.9 mmol/L), with or without 
symptoms, below which the neuroendocrine 
counterregulatory response is physiologically 
activated, prompting the behavioral defense 
of rapid carbohydrate ingestion. The European 
Medicines Agency (EMA), on the other hand 
(in the 2006 note for guidance on clinical 
investigation of medicinal products in the 
treatment of diabetes mellitus), recommended a 
lower threshold of plasma glucose (<3 mmol/L) 
to define hypoglycemia when assessing the 
hypoglycemic risk of different treatment 
regimens, to allow for a more robust detection 
of clinically relevant hypoglycemia.1 Of note, 
most recent trials have consistently defined 
clinically severe hypoglycemia as any episode 
in which a patient is unable to self-treat, and 
thus requires the assistance of another person, 
making the data on severe hypoglycemia less 
subjective and, likely, more reliable.1,4
Mild hypoglycemic events, usually defined 
as self-treated episodes, are more common 
than severe hypoglycemia, but may be 
underreported since most patients do not 
spontaneously describe mild episodes at 
a physician/clinic visit, in part for fear of 
appearing unable to manage their condition.1
Since patients may be unreliable and likely to 
underestimate the frequency with which they 
experience hypoglycemia, patients’ relatives 
and partners should also be questioned, to 
provide a more accurate record of hypoglycemic 
episodes.1,5,6 Despite these limitations, in recent
European Union observational studies, 
over one-third of patients reported having 
mild symptomatic episodes.7,8 The clinical 
consequences of mild hypoglycemia are not 
negligible in many ways, as further outlined 
below. In addition, recurrent mild hypoglycemic 
events lead to hypoglycemia unawareness; 
ie, patients’ inability to perceive the normal 
warning symptoms of hypoglycemia. Indeed, 
antecedent hypoglycemia results in blunted 
neuroendocrine counterregulatory responses 
during subsequent hypoglycemia, leading to 
failure to sense future episodes. It has been 
recently shown that even one prior, relatively 
mild episode of hypoglycemia (of only 3.3±0.1 
mmol/L), may be sufficient to significantly 
blunt physiological defenses against subsequent 
hypoglycemia in modestly advanced T2DM,9
and increase the risk for subsequent severe 
hypoglycemia, perpetrating a vicious circle.2
Severe hypoglycemia becomes more frequent 
in the course of disease progression, with 
dysfunctional counterregulatory responses 
in advanced T2DM,10,11 and it also increases 
with the duration of insulin treatment.12 An 
observational study by the UK Hypoglycaemia 
Study Group found that, for T2DM patients 
treated with insulin for >5 years, the prevalence 
of mild and severe hypoglycemia was similar to 
that for type 1 diabetic patients. However, even 
early insulin use in T2DM was associated with 
a substantial frequency of severe hypoglycemia 
(seen in 7% of patients followed for an average 
of 9 months), which was in fact similar to 
that observed in T2DM patients treated with 
sulfonylureas.13 With sulfonylureas, the risk 
for severe hypoglycemia markedly increases 
with age and with decreasing renal function. 
Patients treated with sulfonylureas from the 
comprehensive community-based database of the 
Diabetes Audit and Research in Tayside Scotland 
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collaboration experienced very severe events 
(defined as requiring emergency treatment from 
primary care, ambulance services, and hospital 
accident and emergency departments) with an 
annual rate of 0.8%.14
In the more recent, Real-Life Effectiveness 
and Care Patterns of Diabetes Management 
(RECAP-DM) observational, cross-sectional study 
conducted in seven European countries over 1 
year, about 5% to 6% of patients with T2DM on 
oral therapy experienced severe hypoglycemic 
episodes requiring assistance.7 In another 
observational, cross-sectional, multicenter study 
conducted in France,8 4% of patients treated with 
a combination of metformin and sulfonylurea 
reported severe hypoglycemia over 6 months. In 
addition, it is worth noting that sylfonylureas 
are not all equivalent in terms of hypoglycemic 
risk, with older sylfonylureas having longer 
time–action characteristics, such as glyburide 
(glibenclamide) or chlorpropamide, being 
associated with greater risk than the second- and 
third-generation agents, such as gliclazide and 
glimepiride.1 Even among the latter, the GlUcose 
control in type 2 diabetes: Diamicron modified 
release (MR) versus glimEpiride (GUIDE) study 
showed that gliclazide MR, while being as 
effective as glimepiride, was associated with 
significantly fewer confirmed hypoglycemic 
episodes, in comparison with glimepiride.15 This 
adds to the heterogeneity in the estimates of 
the prevalence of hypoglycemia reported across 
epidemiological studies.
CLINICAL CONSEQUENCES OF 
HYPOGLYCEMIA 
Hypoglycemia is associated with many 
adverse consequences that may, in some cases, 
counterbalance the benefit of a strict glycemic 
control. The most important aspects are 
described below.
Even Mild Events Have a Detrimental Effect, 
Creating a Barrier to Long-Term Glycemic 
Control
While severe hypoglycemic events can clearly 
have dramatic consequences, especially in older, 
more vulnerable patients, even trivial events 
represent a significant psychological burden 
to patients and an important limiting factor 
in disease management. For patients, there is 
indeed no such thing as a “mild” hypoglycemic 
event in terms of effects and consequences. On 
the one hand, it can lead to reduced willingness 
to take medication as prescribed (reducing or 
omitting doses). On the other hand, it is often 
associated with decreased adherence to diet (with 
“defensive eating” and snacking to prevent and/
or correct hypoglycemia) and exercise avoidance. 
These behavior changes both ultimately 
translate into weight gain, countering the main 
lifestyle message in T2DM management in an 
environment where an estimated 80% to 90% 
of patients need to lose weight.16
Impact of Fear 
In balancing the urge to avoid the acute effects 
of hypoglycemia and the need to prevent long-
term complications, immediate unpleasant 
consequences can be more important to patients 
than future complications.6 The symptoms 
and negative consequences associated with 
hypoglycemia, as well as the higher level of 
variability in blood glucose levels, or the need for 
assistance, may result in major anxiety and fear 
of hypoglycemia, which have significant clinical 
implications for diabetes management.6,17 Fear of 
hypoglycemia impacts on well-being and quality 
of life, and reduces treatment satisfaction and 
adherence to diabetes therapies.7,18-20 A study 
conducted in Cardiff, UK, using data from 
postal surveys among subjects with confirmed 54 Diabetes Ther (2011)  2(2):51-66.
diabetes,20 showed that hypoglycemia was 
associated with a considerable decrement in 
health-related utility (using the EuroQol 5 
Dimensions [EQ-5D] index) as a function of 
increased fear. The RECAP-DM study further 
showed that hypoglycemia was associated with 
significantly lower treatment satisfaction, and a 
number of barriers to treatment adherence.7
Impact of Hypoglycemia on Quality of Life
Many studies have shown that hypoglycemia 
impacts heavily on the well-being and quality of 
life of people with diabetes;7,8,18,19 overall, quality 
of life decreased as the frequency and severity of 
hypoglycemia increased. Consistent with other 
studies, in the French observational study,8 
hypoglycemia was associated with a significant 
reduction in quality of life, as measured with 
EQ-5D, which was apparent in the overall 
summary score and in the anxiety/depression 
and pain/discomfort scales.
Impact of Hypoglycemia on Cost
Data regarding the cost consequences of 
hypoglycemia are still scarce (most are from 
Sweden, Germany, France, and the UK), and 
clearly, more studies are needed. The available 
results, however, indicate that hypoglycemic 
events, especially severe episodes, lead to 
substantial direct and indirect costs of medical 
care and lost productivity.14,19,21-23 For example, 
in one UK study the cost of severe hypoglycemia 
due to T2DM (not including associated costs of 
any injury, disability, or work loss associated 
with the acute event) was estimated at around 
£7.4 million.14 Additionally, one study over a 
6-week period showed that severe hypoglycemia 
resulted in the loss of a mean 8.6 productive 
days per T2DM patient.18 A German study has 
estimated that costs for hypoglycemia in T2DM 
are substantially higher than in type 1 diabetes, 
because of the longer length of hospital stay 
associated with older age, comorbidities, and 
polypharmacy.23
Potential Link to Cardiovascular Morbidity 
and Mortality
Other concerns regarding the consequences 
of hypoglycemia are linked to cardiovascular 
morbidity and mortality.24 Several mechanisms are 
potentially involved. Hypoglycemia has long been 
known as a risk factor for cardiac arrhythmia;25-27
a recent study28 showed that prior exposure to 
hypoglycemia led to impaired cardiovascular 
autonomic function, including decreased cardiac 
vagal baroreflex sensitivity, which may contribute 
to increased cardiovascular morbidity and 
mortality in patients with diabetes. Hypoglycemia 
has also been associated with cardiac ischemia29,30
and prothrombotic changes.31
There has recently been much debate around 
the puzzling findings of the Action to Control 
Cardiovascular Risk in Diabetes (ACCORD) study,2
which had brought to the headlines the question 
of the role of hypoglycemia in increasing the 
risk for cardiovascular events. Retrospective 
analysis of the study32 has confirmed that 
severe hypoglycemia was clearly associated with 
increased risk of death, even if this was true in both 
the intensive and conventional arms, and thus 
did not account for the difference in mortality 
observed between the two study arms. Higher 
mortality was actually seen in patients “resisting” 
to glucose control, with a lack of response to an 
intensified glucose control strategy.33
Hypoglycemia in Vulnerable Populations: 
Elderly and Frail Patients
In the elderly, symptoms of hypoglycemia can 
be particularly difficult to recognize, since elderly Diabetes Ther (2011)  2(2):51-66. 55
patients are more likely to have confusion, 
disorientation, or other neuroglycopenia-
related symptoms that can mimic other medical 
conditions. In addition, older T2DM patients have 
a marked subjective unawareness of hypoglycemia, 
an increased reaction time, and decreased ability to 
take corrective actions, which likely contribute to 
the increased probability of severe hypoglycemia 
reported in these patients.34 Furthermore, severe 
episodes in this age group are associated with 
more serious complications, including falls and 
significant mortality.1,35 A recent longitudinal 
cohort study in a population of older patients with 
T2DM, followed up for 27 years, showed that a 
history of single or multiple severe hypoglycemic 
episodes was associated with a subsequent graded 
increased risk of dementia (adjusted hazard ratio 
[HR] 1.94; 95% confidence interval [CI] 1.42, 
2.64 for patients with three or more episodes) 
independent of glycemic control, treatment, or 
comorbidities.36 On the whole, greater attention 
to the risk of hypoglycemia must be given when 
managing older patients with more advanced 
stages of T2DM.
Need for Early Intervention with Special 
Attention to Minimizing Hypoglycemia
When targeting optimized glycemic control, 
one should not only do it as early as possible 
in the course of the disease, but one should also 
try to minimize hypoglycemia from the start.
Indeed, it is now well recognized that intensive 
therapy should best be implemented early in the 
course of the disease to capitalize on the so-called 
“legacy effect,” as shown in the recently reported 
United Kingdom Prospective Diabetes Study 
(UKPDS) 10-year follow-up study.37 Likewise, it 
may be essential to avoid hypoglycemia very 
early on in the course of the condition, in the 
hope of best preserving counterregulation in the 
long run.9
A recent study showed that intensive 
oral combination therapy and antecedent 
hypoglycemia both produced widespread 
blunting of physiological defenses against 
subsequent hypoglycemia in a group of patients 
with relatively early T2DM (mean duration 
~6 years).9 After 6 months of aggressive glycemic 
control (with triple oral therapy) in this group of 
patients with very poor initial control (glycated 
hemoglobin [HbA1c] 10.2%), near normalization 
of HbA1c (6.7%) resulted in an increased 
frequency to 3.2 for hypoglycemic episodes per 
patient month, with blunted sympatho-adrenal 
counterregulatory responses.9 Amiel and Cryer 
discussed these findings, and suggested that 
good control of diabetes be implemented as 
early as possible, but with special attention to 
minimizing hypoglycemia early in the disease 
process, to prevent loss of counterregulation.38
CLINICAL EXPERIENCE WITH 
VILDAGLIPTIN AT ALL STAGES OF 
T2DM
Dipeptidyl peptidase-4 (DPP-4) inhibitors 
bind and inhibit the enzyme that cleaves and 
inactivates the two principal incretins, glucagon-
like peptide-1 (GLP-1) and gastric inhibitory 
polypeptide (GIP). Incretins are short-lived 
hormones released from the gut in response to 
food intake, and are responsible for the boost 
in insulin secretion that occurs following an 
oral glucose load. This occurs in a glucose-
dependent manner, unlike indiscriminate 
insulin secretagogues, such as sulfonylureas 
and glinides. This glucose-dependent “fail-safe” 
prevents even elevated incretin levels from 
overstimulating insulin secretion in the absence 
of elevated or rising glucose levels. Thus, incretin-
based therapies are generally associated with a 
rather low hypoglycemic risk, and, due in part 
to less hypoglycemia-related defensive eating, 56 Diabetes Ther (2011)  2(2):51-66.
they are also associated with weight neutrality. 
In contrast to GLP-1 receptor agonists, DPP-4 
inhibitors prolong the activity and enhance the 
action of endogenous incretins, physiologically, 
at the time of their secretion.39
The DPP-4 inhibitor vildagliptin has been 
studied in a large clinical development program, 
showing good overall safety and tolerability, 
and improved glycemic control when given as 
monotherapy or combination therapy, with a 
low risk of hypoglycemia. Across all vildagliptin 
phase 3 studies, hypoglycemia was consistently 
defined as symptoms suggestive of low blood 
glucose (<3.1 mmol/L plasma glucose equivalent) 
confirmed by self-monitored blood glucose 
measurement.40 Severe hypoglycemia was defined 
as any episode requiring assistance by another 
party. Hypoglycemia data with vildagliptin 
are available across the T2DM spectrum, with 
particularly noteworthy results at both ends of 
the disease spectrum, as reviewed below. 
Vildagliptin Monotherapy in Prediabetes 
and Patients with Early Diabetes/Mild 
Hyperglycemia
In nondiabetic (normal glycemic) individuals, 
vildagliptin does not stimulate insulin secretion, 
nor does it reduce glucose levels. However, the 
known effects of vildagliptin on incretin levels 
and islet function in T2DM are seen as early 
as in subjects with impaired glucose tolerance 
(IGT) or impaired fasting glucose (IFG).41,42 A 
12-week study in 179 subjects with IGT exposed 
to vildagliptin 50 mg once daily (q.d.) or placebo 
showed a 32% reduction in postprandial glucose 
excursions, with no evidence of hypoglycemia.41
Similarly, in a phase 3 study in patients with early 
T2DM and mild hyperglycemia (mean HbA1c at 
baseline 6.7%; n=306), who were thus at increased 
risk for hypoglycemia with anti-diabetic therapy, 
1-year treatment with vildagliptin (50 mg q.d.) 
resulted in a significant HbA1c difference of 
–0.3% versus placebo, with no hypoglycemia 
reported in vildagliptin-treated patients.43 The 
lack of hypoglycemia is even more remarkable 
considering that approximately half (n=144) 
of the randomized patients were ≥65 years, a 
population known to be particularly susceptible 
to hypoglycemia. Moreover, no vildagliptin-
treated patients experienced hypoglycemia 
during a further 1-year extension study, despite 
continued improvement in glycemic control 
(significant difference of 0.5% vs. placebo), while 
two hypoglycemic events occurred in patients 
receiving placebo during the overall 2-year study 
period.44
Vildagliptin Monotherapy in the Broad 
T2DM Population
Several phase 3 studies assessed vildagliptin 
monotherapy in patients with more advanced 
hyperglycemia than the studies discussed in 
the previous section, yet still drug naive (mean 
baseline HbA1c 8.4% to 8.7%). Across these eight 
monotherapy studies of 24 weeks to 2 years’ 
duration,45-52 no severe hypoglycemia and a 
very low incidence of nonsevere episodes (0% 
to 0.7% with vildagliptin 100 mg/day) was 
observed in vildagliptin-treated patients, despite 
robust improvements in HbA1c of, on average, 
~1%. Also of particular interest is an additional 
monotherapy study in elderly patients ≥65 years 
of age (mean 71 years), in which the mean 
HbA1c after 24 weeks was reduced to 7.1% 
with vildagliptin (100 mg q.d.) and 7.0% with 
metformin (1500 mg/day) from a baseline 
HbA1c of 7.8% and 7.7%, respectively.53 Despite 
the low mean HbA1c achieved at endpoint 
in this more vulnerable population, a low 
incidence of hypoglycemia was observed in 
both treatment groups, with no hypoglycemia 
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patients, while two elderly patients receiving 
metformin experienced mild hypoglycemic 
episodes.53 A favorable hypoglycemia profile 
for vildagliptin in elderly patients was also seen 
in a pooled analysis of 374 drug-naive patients 
aged ≥65 years (mean age 70 years) treated with 
vildagliptin monotherapy.54 While a robust 
HbA1c reduction of 1.2% (baseline 8.3%) was 
seen, hypoglycemia occurred in only 0.8% of the 
elderly vildagliptin-treated population, with all 
of the episodes considered mild.54
Recently, clinical experience with vildagliptin 
in a patient population with T2DM aged ≥75 years 
has been published from a pooled analysis of 
phase 2 and 3 clinical trials, and no confirmed 
hypoglycemic events, including no severe events, 
were reported in this very elderly population.55
Combination Therapy of Vildagliptin with 
Other Oral Anti-diabetic Agents (OAD)
Combination Therapy with Metformin
Several phase 3 studies of 24 weeks to 2 years’ 
duration evaluated vildagliptin as add-on 
therapy to metformin. Most of these studies 
had a mean baseline HbA1c of approximately 
8.4%, and reported no severe hypoglycemia, 
and a very low incidence of nonsevere episodes 
(0.3% to 1.0% with vildagliptin 100 mg/
day),56-59 comparable to what was seen with 
monotherapy. Also, as described above for 
monotherapy, trials evaluating add-on therapy 
to metformin in T2DM patients who have mild 
hyperglycemia and are thus at increased risk for 
hypoglycemia with glucose-lowering treatment, 
are most relevant to assess the hypoglycemic 
potential of therapy. In such a study where 
the mean baseline HbA1c was 7.3%, a total 
of 2789 patients already receiving maximum 
tolerated doses of metformin were randomized 
to receive either vildagliptin (50 mg twice daily 
[b.i.d.]) or glimepiride (up to 6 mg/day) for 1 
year.60 While the efficacy was similar between 
the two treatment arms (noninferiority was 
achieved, with mean HbA1c 6.75% and 6.71% at 
1 year, respectively), vildagliptin was associated 
with significant reductions in the frequency 
and severity of hypoglycemia. Hypoglycemia 
occurred in 1.7% of vildagliptin-treated patients 
(39 episodes), compared to 16.2% of glimepiride-
treated patients (554 episodes) (P<0.01), with 
0 versus 10 severe episodes (P<0.01), and 0 
versus 11 patients discontinuing study treatment 
because of hypoglycemia (Figure 1).60
These results were confirmed following an 
additional 1-year treatment period.61 Of note 
this benefit on hypoglycemia was also seen 
over a period of 2 years in a large group of 
elderly patients (n=789), with 2.1% of patients 
experiencing at least one hypoglycemic event 
(18 events) in the vildagliptin group, versus 
17.5% (202 events) of patients in the glimepiride 
group (P<0.001).61 The neuroglucopenic 
symptoms associated with confirmed 
hypoglycemia occurred much less often with 
vildagliptin than glimepiride; there were no 
occurrences of confusional state/disorientation, 
vertigo/balance disorder/dystasia (unsteadiness)/
motion sickness, and malaise/syncope in 
patients treated with vildagliptin, compared 
with 34, 45, and 25 occurrences, respectively, 
with glimepiride (Table 1).61
Vildagliptin was also studied as initial 
combination therapy with metformin in
drug-naive T2DM patients (baseline HbA1c
8.7%), with no hypoglycemic episodes reported 
with the fixed dose combination of vildagliptin 
and metformin (vildagliptin 50 mg b.i.d., plus 
either low-dose [500 mg b.i.d.] or high-dose 
[1000 mg b.i.d.] metformin) over the 24-week 
treatment period, despite large reductions in 
HbA1c of 1.6% and 1.8%, respectively.52
Data with other DPP-4 inhibitors and GLP-1 
analogs in combination with metformin confirm 58 Diabetes Ther (2011)  2(2):51-66.
a favorable hypoglycemia profile for GLP-1 based 
therapies;62 for example, when compared to a 
sulphonylurea as add-on therapy to metformin, 
the incidence of hypoglycemia was 5% with 
sitagliptin, versus 32% with glipizide.63
Combination Therapy with 
Thiazolidinediones
The incidence of hypoglycemia was also very 
low in patients receiving vildagliptin (50 mg 
q.d. or b.i.d.) added to pioglitazone (≤0.6%), 
and even somewhat lower than with placebo 
added to pioglitazone (1.9%).64 There were no 
severe events reported. HbA1c was reduced by up 
to 1.0% with vildagliptin in this 24-week study.
A similar hypoglycemia profile was seen in an 
initial combination therapy study of vildagliptin 
and pioglitazone in drug-naive T2DM patients 
(baseline HbA1c 8.7%).46 HbA1c was reduced by 
1.9% (vildagliptin 100 mg q.d. plus pioglitazone 
30 mg q.d.) and 1.7% (vildagliptin 50 mg q.d. 
plus pioglitazone 15 mg q.d.), respectively, with 
corresponding hypoglycemia incidences of 0.7% 
and 0%; ie, only one mild episode reported.46
Combination Therapy with Sulphonylureas
When vildagliptin was added to a sulphonylurea 
(glimepiride 4 mg q.d.) in a 24-week study, 
HbA1c decreased by 0.6% from an 8.5% baseline 
Table 1. Symptoms associated with confirmed 
hypoglycemia with vildagliptin and glimepiride during 
2-year treatment (safety population; n=1553, vildagliptin 
group; n=1546, glimepiride group).61 Table shows the 
most concerning symptoms associated with confirmed 
hypoglycemic episodes (neuroglucopenia).
  Number of occurrences 
Symptom  Vildagliptin  Glimepiride
Confusion state/disorientation  0  34
Vertigo/balance disorders/ 
unsteadiness   0  45
Malaise/syncope  0  25
Altered vision  3  71
Adapted with permission from: Matthews DR, Dejager S, 
Ahren B, et al. Vildagliptin add-on to metformin produces 
similar efficacy and reduced hypoglycaemic risk compared 
with glimepiride, with no weight gain: results from a 2-year 
study. Diabetes Obes Metab. 2010;12:780-789.
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Figure 1. Incidence and severity of hypoglycemic events with vildagliptin and glimepiride during 1-year treatment 
(safety population; n=1389, vildagliptin group; n=1383, glimepiride group).60 *P<0.01 between groups; b.i.d.=twice daily; 
q.d.=once daily. Adapted with permission from: Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of 
vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes 
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with both vildagliptin 50 mg q.d. and 50 mg 
b.i.d., versus an increase of 0.1% with placebo.65 
The incidence of hypoglycemic events was 
low, but slightly higher in the group receiving 
vildagliptin 50 mg b.i.d. (3.6%) than in the 
group receiving vildagliptin 50 mg q.d. (1.2%) 
or placebo (0.6%). All hypoglycemic episodes on 
vildagliptin therapy were mild, while there was 
one severe episode with placebo.65
In a second add-on to sulphonylurea study, 
vildagliptin 50 mg b.i.d. or placebo were added 
to glimepiride (mean daily dose 2.5 mg) in 
Japanese patients.66 After 12 weeks of treatment, 
HbA1c changes from a baseline of approximately 
8% were –1.0% with vildagliptin and –0.06% 
with placebo. Despite the low HbA1c at endpoint, 
the incidence of hypoglycemia was low (2% with 
vildagliptin 50 mg b.i.d., and 1% with placebo), 
and all events were mild (grade 1).66
Of note is that at the HbA1c levels achieved 
through DPP-4 inhibition, the insulinotropic 
effects of endogenous GLP-1 are known to be 
strictly glucose dependent and, accordingly, 
hypoglycemia is rare when vildagliptin is 
given as monotherapy, or in combination with 
metformin or a thiazolidinedione. A potential 
explanation for the slightly higher incidence 
of hypoglycemia reported with vildagliptin 
and other DPP-4 inhibitors when given in 
combination therapy with sulphonylureas67 may 
be provided by a study by de Heer and Holst.68
It was found that sulphonylureas in the 
perfused rat pancreas appear to “uncouple” 
the glucose dependence of GLP-1’s effects on 
pancreatic hormone secretion.68 Nonetheless, 
a study by El Ouaghlidi and colleagues69
demonstrated that in healthy volunteers, 
vildagliptin did not exacerbate the more serious 
hypoglycemia induced by sulphonylurea 
administration. The fact that all events were 
mild in the clinical studies of vildagliptin and 
sulphonylurea combination therapy in T2DM 
patients also suggests some degree of glucose 
dependency.65,66
In contrast, a marked increase in the risk of 
hypoglycemia has been reported when GLP-1 
analogs are combined with sulphonylureas,70,71 
and a reduction in the dose of sulphonylurea is 
generally recommended to reduce this risk. For 
example, the incidence of hypoglycemia was 
14% and 36% with exenatide 5 µg and 10 µg, 
respectively, added to sulphonylurea, compared 
to 3% for placebo added to sulphonylurea.70
GLP-1 is only glucose-sensitive at 
physiological GLP-1 concentrations, while at 
pharmacological GLP-1 levels, there is also a 
nonglucose-dependent stimulation of insulin 
secretion.72 DPP-4 inhibitors only prolong 
GLP-1 levels following nutrient-stimulated 
GLP-1 secretion, and therefore the physiological 
glucose-dependency of GLP-1 is preserved, while 
this may not be the case for GLP-1 analogs 
injected at pharmacological doses. Furthermore, 
with DPP-4 inhibitors, glucose-sensitive GIP-
stimulation of glucagon secretion may be 
maximized under hypoglycemia.73
Combination Therapy with Insulin
Hypoglycemia data of particular interest were 
obtained with vildagliptin in patients with 
advanced disease (mean diabetes duration 
~15 years) receiving long-standing (~6 years) 
insulin treatment.74,75 When vildagliptin (50 mg 
b.i.d.) was added to insulin monotherapy in 
patients with baseline HbA1c 8.4% and mean 
daily insulin dose of 82 U, a reduction in HbA1c 
of 0.5% from baseline was seen after 24 weeks 
(P=0.01 vs. placebo, with no change in insulin 
doses).74 Despite the greater reduction in HbA1c, 
hypoglycemic episodes were less frequent and 
less severe with vildagliptin treatment, compared 
to placebo. With vildagliptin added to insulin, 
33 patients experienced a total of 113 events, 
while with placebo added to insulin, 45 patients 60 Diabetes Ther (2011)  2(2):51-66.
experienced a total of 185 events.74 Importantly, 
there were six severe hypoglycemic events 
(requiring the assistance of another person) in 
the placebo-plus-insulin group, but no severe 
events in the vildagliptin-plus-insulin group 
(Figure 2).74 In a double-blind 28-week extension 
of the study, the hypoglycemia benefit was still 
evident.75
It is worth noting that no such reduction in 
hypoglycemia has been reported thus far with 
other DPP4-inhibitors in combination with 
insulin. In a clinical trial that investigated the 
addition of sitagliptin (100 mg q.d.) to insulin, 
an increased incidence of hypoglycemia (16%) 
was reported with sitagliptin, compared with 
placebo (8%), and there were two episodes 
with sitagliptin that met the protocol-specified 
criteria for severity, versus one such episode with 
placebo.76 While the reason for these different 
results remains to be further investigated, an 
interesting observation, which could provide 
a mechanistic basis, comes from a study by 
Marfella and colleagues77 in patients treated 
with metformin. In this study, the addition of 
vildagliptin (50 mg b.i.d.) was found to cause a 
more prolonged increase in active GLP-1 during 
the intraprandial period than the addition of 
sitagliptin (100 mg q.d.).  
REAL-LIFE EXPERIENCE
The hypoglycemia profile described with 
vildagliptin in clinical studies is further supported 
by results from a “real-world” study, in which 
52 Muslim patients with T2DM in north west 
London, UK, were followed during the Ramadan 
fasting period (no food or drink consumed 
from sunrise to sunset for a lunar month).
Patients entered the observational period with 
HbA1c >8.5% despite metformin treatment, and 
were given either vildagliptin (50 mg b.i.d., 
n=26) or gliclazide (160 mg b.i.d., n=26), starting 
2 weeks prior to the fast. At approximately 10 
days after the Ramadan fasting period, glycemic 
control was comparable in the two groups (HbA1c
7.7% with vildagliptin and 7.8% with gliclazide). 
However, hypoglycemia occurred in only two 
patients treated with vildagliptin, compared 
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with 16 patients treated with gliclazide (7.7% 
vs. 61.5%, respectively; P<0.001), with severe 
hypoglycemia occurring in one gliclazide-treated 
patient and in none of the vildagliptin-treated 
patients.78
Taken together, vildagliptin treatment 
has consistently been associated with a low 
incidence of hypoglycemia in all clinical 
settings, including more vulnerable populations 
at higher risk for hypoglycemia, such as elderly 
patients or patients treated with insulin. This 
was again recently confirmed in a T2DM patient 
population ≥75 years of age (based on a new 
pooled analysis of phase 2 and 3 clinical trials) 
in whom no confirmed hypoglycemic events, 
including no severe events, were reported.55
This benefit stems from a solid mechanistic 
basis, including initial data suggesting that 
vildagliptin may enhance the glucagon response 
to hypoglycemia.
MECHANISTIC BASIS FOR THE 
LOW RISK OF HYPOGLYCEMIA
Among the glucose counterregulatory factors, 
glucagon plays a primary role,79 and even in 
modestly advanced T2DM, multiple defects 
already exist in hormonal responses to 
hypoglycemia, including delayed and reduced 
decreases in insulin secretion and impaired 
increases of plasma glucagon and growth 
hormone.80 Therefore, preserving this response is 
essential to minimize the risk of hypoglycemia 
with any given agent. It has previously 
been shown that, while metformin does not 
adversely affect the counterregulatory response 
to hypoglycemia,81 sulfonylureas significantly 
impair the glucagon response in T2DM patients.82
To evaluate whether vildagliptin would affect 
the hormonal counterregulatory response to 
hypoglycemia, the influence of 28-day treatment 
with vildagliptin (vs. placebo, in a double-blind 
crossover design) on the glucagon response to 
both hyper- and hypoglycemia was examined 
in patients with T2DM: standard breakfast meal 
tests were performed followed by stepped glucose 
clamps (7.5, 5.0, and 2.5 mmol/L glucose).83
This study showed that vildagliptin 
significantly increased (by 38%) the glucagon 
increment during hypoglycemic clamp, yet 
reduced (by 41%) the incremental postprandial 
glucagon area under the concentration–
time curve (AUC)0-60min, thus improving both 
the action of glucose to suppress glucagon 
secretion during hyperglycemia (seen during 
meal ingestion), and the augmenting effect 
of hypoglycemia on glucagon secretion (seen 
during the stepped hypoglycemic clamp) 
(Figure 3). The effect could be mediated in part 
via the autonomic nervous system, because it 
was accompanied by enhanced stimulation of 
pancreatic polypeptide secretion (an index of 
vagal input to the pancreas).83
Additionally, the study found that the 
decrease in insulin secretion rate during 
hypoglycemia was more pronounced with 
vildagliptin than with placebo, being the first 
demonstration that a DPP-4 inhibitor enhanced 
the effectiveness of low glucose levels to suppress 
insulin secretion.83 While this observation would 
support the intra-islet hypothesis (the concept 
that glucagon secretion is essentially mediated 
by local insulin levels), it should be noted that 
vildagliptin was recently shown to exert its 
suppressive effect on glucagon secretion in the 
absence of endogenous insulin in insulinopenic 
patients with type 1 diabetes (thus independent 
of a paracrine effect of insulin).84 Furthermore, 
the glucagon response to hypoglycemia is now 
being investigated in insulin-treated patients 
with T2DM (ClinicalTrials.gov identifier: 
NCT01219400), and in type 1 diabetic patients 
treated with vildagliptin (ClinicalTrials.gov 
identifier: NCT01147276) in two studies. 62 Diabetes Ther (2011)  2(2):51-66.
CONCLUSION
These initial mechanistic data provide evidence 
that DPP-4 inhibition with vildagliptin improves 
both α- and β-cell glucose sensing, augmenting 
the effects of hypoglycemia, both to stimulate 
glucagon release and to suppress insulin 
secretion.83 This may explain earlier findings 
that hypoglycemic episodes in patients with 
T2DM were less frequent and less severe with 
vildagliptin versus placebo added to insulin 
therapy.74,75 It may also explain the overall low 
risk of hypoglycemia with vildagliptin, which is 
extensively documented throughout the clinical 
development program across a wide range of 
clinical settings. 
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